Olympus (OTCMKTS:OCPNY – Get Free Report) and Pro-Dex (NASDAQ:PDEX – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Olympus and Pro-Dex, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Olympus | 0 | 0 | 1 | 0 | 3.00 |
| Pro-Dex | 0 | 1 | 2 | 0 | 2.67 |
Pro-Dex has a consensus price target of $80.00, indicating a potential upside of 25.12%. Given Pro-Dex’s higher probable upside, analysts plainly believe Pro-Dex is more favorable than Olympus.
Volatility and Risk
Olympus has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.
Earnings & Valuation
This table compares Olympus and Pro-Dex”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Olympus | $7.74 billion | 2.99 | $1.03 billion | $0.82 | 21.95 |
| Pro-Dex | $77.55 million | 2.64 | $13.66 million | $3.65 | 17.52 |
Olympus has higher revenue and earnings than Pro-Dex. Pro-Dex is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Olympus and Pro-Dex’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Olympus | 13.80% | 24.30% | 9.30% |
| Pro-Dex | 15.12% | 26.18% | 16.69% |
Insider & Institutional Ownership
0.0% of Olympus shares are held by institutional investors. Comparatively, 15.3% of Pro-Dex shares are held by institutional investors. 48.0% of Pro-Dex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Pro-Dex beats Olympus on 8 of the 14 factors compared between the two stocks.
About Olympus
Olympus Corporation is a Japan-based medical technology company focused on developing and supplying equipment and services for medical procedures. Its products include gastrointestinal endoscopes and related systems, surgical endoscopes, and endotherapy devices used in diagnosis and treatment. The company’s roots date to 1919, when it was established in Japan as Takachiho Seisakusho to produce microscopes. Over time, Olympus became known for optical products, but it has since exited its camera and scientific solutions businesses to concentrate on medical technology.
About Pro-Dex
Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments and related accessories, with a focus on devices used in orthopedic procedures. Its products include surgical handpieces and drivers, along with the components and systems that support their operation. The company also provides engineering, product development and manufacturing services to medical device companies. Its work can span the product lifecycle, from design and prototyping to production and servicing. Founded in 1978, Pro-Dex is headquartered in Irvine, California, and serves customers in the United States and international markets.
Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.
